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February 2016 Abstracts S29dose-dependent manner and signiﬁcantly extended
survival of the mice.
Conclusions: These results provide comprehensive evi-
dence for the oncogenic functions of L-Myc and further
support the concept of targeting the gene and its related
molecular pathways to intervene in SCLC. Additionally,
the new approaches demonstrated in this study will
facilitate functional analysis of numerous candidate
genes, increasing the likelihood of determining cancer-
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Medicine, New Haven, CTLung cancer remains a major cause of cancer mortality in
the world. There is a signiﬁcant need to develop new
strategies that provide effective treatment for lung can-
cer. Current study reports that targeting oncogenic
transcription factors could be a potential treatment
method for lung cancer. The E2F transcription factor
family members have been shown to be involved in
cancer development. The E2F members have been
divided into transcription activators (E2F1-E2F3) and
repressors (E2F4-E2F8). E2F8 with E2F7 has been
known to play an important physiologic role in embry-
onic development and cell cycle regulation by repressing
E2F1. We found that E2F8, an E2F transcription factor
family member, is overexpressed in lung cancer cell lines
and tumors from lung cancer patients compared with
normal lung cells and tissues, as determined by immu-
noblotting or immunoﬂuorescence staining in human
lung cancer cells and tissues from lung cancer patients.
Kaplan-Meier analysis of data from a public database
showed that aberrantly overexpressed E2F8 in patients
with lung cancer is associated with worse prognosis.
Depletion of E2F8 inhibited cell proliferation, colony
formation, invasion and tumor growth in vitro and in
vivo, while growth of normal cells was not affected by
the loss of E2F8. In addition, depletion of E2F8 induced
substantial DNA damage in cancer cells but not in
normal cells. Moreover, targeting E2F8 using its speciﬁc
siRNAs and morpholino-modiﬁed antisense dramatically
suppressed tumor growth in in vivo studies using mouse
models, including s.c. xenograft in nude mice, syngeneic
mouse lung cancer model, and a transgenic lung cancer
mouse model. To identify genes regulated by E2F8, we
performed microarray analyses using human lung cancer
cell lines (NCI-H1975, H441, and H520) and AffymetrixHuman Genome Arrays. Bioinformatical analyses
revealed that knockdown of E2F8 deregulated gene sets
involved in regulation of transcription, cancer progres-
sion, chromatin organization, regulation of immune
system, glutamate receptor signaling, and cell surface
receptor signaling. Further analysis of E2F8 binding
motif using chromatin immunoprecipitation (ChIP) as-
says combined with sequencing (ChIP-Seq) method, we
identiﬁed genome-wide distribution of 204 E2F8 binding
sites. From the microarray analysis and ChIP-Seq assay,
we identiﬁed the UHRF1 (ubiquitin-like PHD and RING
domain-containing 1), critical for DNA replication of
cancer cells, as one of the E2F8 target genes. In conclu-
sion, we report that E2F8 is overexpressed in lung can-
cer and is required for the growth of lung cancer cells.
The E2F8 knockdown signiﬁcantly perturbed genes
involved in the DNA replication pathway in cancer cells.
These ﬁndings provide evidence that E2F8 is a novel
therapeutic target for lung cancer treatment.Rare but poor prognosis of TERT
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The mutation in the promoter region of telomerase
reverse transcriptase (TERT) and telomere length
have been focused in various cancers. In present
study, the frequency and clinical characteristics of
TERT promoter mutation and telomere length were
studied in non-small cell lung cancers (NSCLC). TERT
promoter mutation and telomere length were analyzed
in 188 patients by using sequencing and real-time
PCR, respectively. The TERT promoter mutation rate
was 2.2% (4/188) of NSCLC and it was associated
with regional lymph node invasion (p < 0.001) and
poor differentiation (p ¼ 0.060). Telomere length was
not associated with TERT promoter mutation and it
divided into high and low groups by median value
(3.04). Telomere length was shorter in males (p ¼
0.058) and smokers (p ¼ 0.008). Survival analyses
showed a poor prognosis of NSCLC with TERT pro-
moter mutation (p < 0.001). Multivariate survival
analyses demonstrated that TERT promoter mutation
was associated with poor overall survival (p ¼ 0.045).
These data demonstrated TERT promoter mutation
was not frequent in NSCLC, however, it might have a
potential value for prognostic factor in NSCLC.
